INTRODUCTION
Cyclosporine (CsA), a selective immunosuppressor, is increasingly used in veterinary medicine to treat a variety of conditions in dogs and cats (Palmeiro, 2013) . Recently cyclosporine oral solution received approval by the US Food and Drug Administration (US FDA) as ATOPICA for Cats â (cyclosporine oral solution, USP) MODIFIED (NADA #141-329; Novartis Animal Health US, Inc. (NAH), Greensboro, NC, USA) for the control of feline hypersensitivity dermatitis (HD) in cats. It is a cyclic polypeptide that exerts anti-inflammatory and antipruritic effects in the treatment of allergic dermatitis by preferentially inhibiting the activation of T-lymphocytes on antigenic stimulation through impairing the production of IL-2 and other Tcell-derived cytokines (Robson, 2003b) . In addition, CsA has the capacity to inhibit the antigen-presenting function of the skin immune system and block the recruitment and activation of eosinophils, the production of cytokines by keratinocytes, the function of Langerhans cells, the degranulation of mast cells and therefore the release of histamine and pro-inflammatory cytokines (Robson, 2003b) . Adverse effects attributed to CsA use in humans include convulsions, fever, vomiting, diarrhea, high blood pressure, potassium retention, and kidney and liver dysfunction. In cats, few adverse reactions to CsA have been reported, with gastrointestinal signs (diarrhea, vomiting, and anorexia) , the most frequently observed reactions (Robson, 2003a; Noli & Scarampella, 2006; Vercelli et al., 2006; Wisselink & Willemse, 2009; King et al., 2012) . Similar dose-dependent, reversible adverse reactions are also observed in dogs. However, there are species differences (Robson, 2003a) . For example, CsA is metabolized much more slowly by rat liver cells than by dog liver cells (Whalen et al., 1999) . Further, unlike dogs, rats tend to accumulate the drug in plasma and tissues and thus are very susceptible to hepato-and nephrotoxicity, with significant mortality occurring at doses of 45 mg/kg/day (Ryffel, 1982) . It has also been suggested that the blood concentration of cyclosporine may increase over time due to saturation of the tissue-binding sites (Vaden, 1997; Tanaka et al., 2000) . Such accumulation could increase the risk of toxicity during longterm therapy.
This study was conducted to determine the safety and tolerability of a cyclosporine oral microemulsion formulation (ATO-PICA for Cats) when repeatedly administered orally for 6 months to adult cats at high doses. Further, the pharmacokinetics of cyclosporine over the 6-month period was assessed to identify if unexpected accumulation occurs in cats.
MATERIALS AND METHODS

Animals
Forty domestic short-hair cats (20 males and 20 females), approximately 6 months old and weighing between 1.86 and 5.00 kg on Day 1 prior to treatment, were enrolled in a 183-day (6 months) study. These laboratory purpose-bred cats were in good health as determined by a comprehensive physical examination (including neurological assessment) performed by a licensed veterinarian and the results of fecal examination for parasites, clinical pathology (hematology, clinical chemistry, urinalysis), and ophthalmological (performed by a board certified veterinary ophthalmologist), blood pressure and electrocardiographic examinations (a board certified veterinary cardiologist provided a qualitative, quantitative review and report).
Cats were acclimated for approximately 3 weeks prior to study start, housed individually, each with perches, litter pans and enrichment toys, in an environmentally controlled room (room temperature: 64-84°F; humidity: 30-70%; 12-h light/dark cycle) and were uniquely identified by microchip and ear tattoo. Lab Diet ™ (Certified Feline Diet #5003; PMI Nutrition International, Inc., Richmond, IN, USA) and municipal tap water were available ad libitum, except during designated periods.
Study design
This study was a masked, randomized parallel design study with the individual cat as the experimental unit. 
Investigational treatment administration
A final formulation of cyclosporine oral solution, USP MODI-FIED (microemulsion solution at 100 mg/mL: ATOPICA for Cats, Novartis Animal Health) was used. Cats were blocked and randomized according to sex and body weight to either a negative control group receiving no treatment or to one of four treatment groups receiving either 19 (8 mg/kg/day), 29 (16 mg/kg/day), 39 (24 mg/kg/day) or 59 (40 mg/kg/day) the maximum therapeutic dose (8 mg/kg/day). All cats were dosed once daily for 183 consecutive days (6 months), after fasting for 8 h and approximately 2 h before being fed; Day 1 was defined as the first day of treatment. Treatments were administered by unmasked individuals who were not involved in any other assessments. Cyclosporine microemulsion solution was administered into the back of the oral cavity and followed by 1 mL of tap water to ensure adequate ingestion. Doses were calculated based on the most recent body weight. The control group was sham dosed with an empty syringe followed by a 1 mL rinse of tap water in the same manner as the treated groups.
In vivo observations
Cats were observed twice a day throughout the study for morbidity, mortality, injury, and the availability of food and water. Baseline values for body weight and feed consumption were established during acclimation. During treatment administration, body weight was recorded and feed consumption was calculated on a weekly basis.
Detailed clinical observations by a trained technician were made twice daily, approximately 1 and 7 h after dosing. At a minimum, the following was evaluated at each observation: eyes, mucus membranes, respiratory system, circulatory system, autonomic and central nervous systems, somatomotor activity behavior pattern and gastrointestinal system (inappetence, emesis, stool abnormalities and diarrhea). Particular attention was given to the presence of clinical signs indicative of cyclosporine toxicity in cats (lethargy/depression, ataxia, imbalance, anorexia, vomiting, diarrhea, and gingival hypertrophy). A staff veterinarian was available, if necessary, to further investigate any abnormalities.
Ophthalmic examinations were performed by a veterinary ophthalmologist once during acclimation and again prior to necropsy. A licensed veterinarian completed a physical examination, including neurological assessment and blood pressure measurement, on each cat twice during acclimation and at least once monthly during the treatment phase. At a minimum, the following was evaluated at each examination: general health, behavior, body temperature, mucous membranes, integument, equilibrium/coordination, body condition, cardiovascular, respiratory, renal, urogenital, gastrointestinal, musculoskeletal, reproductive system and ocular. Prior to initiation of dosing and on Days 178 or 180, under sedation (acepromazine/ketamine), electrocardiography was performed by a board certified cardiologist. Standard ECGs (10 Lead) were recorded at 50 mm/sec. Using Lead II, the RR, PR, and QT intervals, and QRS duration were measured and recorded. Heart rate was calculated from the number of ECG complexes in 10 sec. At all times during the dosing period, it was possible to withdraw and euthanize any cat for humane reasons.
Clinical pathology
Blood samples for hematology, coagulation (activated partial thromboplastin time and prothrombin time) and clinical chemistry were collected from all cats (fasted overnight) during acclimation and approximately 24 h following the dosing on Days 7, 31, 91, 154, and 183. Urine was also collected on the same occasion by replacing litter with NoSorb â (Catco Inc., Cape Coral, FL, USA) for 16-24 h. Samples were handled and processed according to standard procedures by a diagnostic laboratory.
Pharmacokinetic analysis
Blood samples were collected from fasted cats between 30 and 60 min prior to dosing on Days 1, 2, 7, 14, 31, 91, 154 and 182. In addition, on Days 1 and 31, blood was collected at 1 and 4 h after the dose, and on Day 182 blood was collected at 1, 2, 4, 8, and 24 h after the dose. Whole blood samples were stored frozen at approximately À70°C and sent to Novartis Centre de Recherche Sante Animale SA, St-Aubin, Switzerland, for analysis by high performance liquid chromatography (HPLC) with mass selective detection (LC-MS) method validated for a range of approximately 3-250 ng/mL cyclosporine A. The analytical laboratory was blinded. Cyclosporine D (Novartis Pharma AG, Basel, Switzerland) was used as an internal standard. Spiked (fortified) specimens covering the analytical range of concentrations of cyclosporine A were prepared using untreated blood to establish the calibration curve by quadratic regression. This curve enabled the recovery corrected determination of cyclosporine A in unknown specimens. Recoveries of cyclosporine A and the internal standards were calculated for spiked blood specimens by comparison of peak areas to those collected for standard solutions without extraction. The lower limit of quantification (LLOQ) for cyclosporine A in this study was 2.95 ng/mL.
Necropsy and histopathology
Cats were euthanized by an intravenous overdose of sodium pentobarbital solution followed by exsanguination. A gross examination was conducted and full complement of organs, and tissues were collected under the supervision of a veterinary pathologist. Organs were removed, examined, weighed (paired organs were weighed together), and where indicated, placed in neutral-buffered formalin for fixation. Eyes and testes were fixed in modified Davidson's fixative, and lungs were infused with formalin. Representative samples of organs and tissues, as well as any gross lesions found, were prepared and processed using standard histological methods. Paraffin sections were stained with hematoxylin-eosin, and slides were examined by a veterinary pathologist using a 4-step grading system (trace, mild, moderate, and severe).
Statistical analysis
Summary statistics (mean and standard deviation) were provided for all variables. SAS (SAS Institute, Inc., Cary, NC, USA) was utilized for all analyses. Analysis of variance (ANOVA) was conducted on any endpoint measured only once (organ weights). Endpoints measured multiple times during the study and having a pretreatment measurement (body weight, food consumption, blood pressure, clinical chemistry, hematology, coagulation, and urinalysis parameters) were analyzed using a repeated measures analysis of covariance (RMANCOVA). Body weight change from baseline was analyzed using a repeated measures analysis of variance (RMANOVA). P-values of <0.10 were considered significant for the treatment fixed effect and treatment-by-time interaction; all other interactions were considered significant at P < 0.05. Pharmacokinetic data were evaluated by noncompartmental analysis to determine C max , T max , and AUC 0-last . T 1/2 and AUC 0-infinity were not estimated due to the chosen sampling scheme (too few sampling points after the last administration to estimate the terminal slope). Dose-dependent pharmacokinetic parameters (AUC and C max ) were additionally normalized with respect to dose (C max_N and AUC 0-last_N , respectively). After applying a log transformation, T max values were checked to see if they satisfied the normal distribution assumption. Summary statistics (arithmetic and geometric mean, median, standard deviation, coefficient of variation, minimum and maximum values) were provided.
RESULTS
Observations
There were no treatment-related adverse findings from the clinical observations, physical examinations including neurological assessments, blood pressure, quantitative ECG parameters or ophthalmologic assessments, in any cat. Intermittent interventricular conduction disturbances were observed on the electrocardiogram in one 39 male and one 59 female during month 6 of treatment. In addition, in treated male cats, a dose-dependent increase in the frequency of soft feces was observed. There was one unscheduled death, a female dosed at 40 mg/kg/day, which was euthanized in extremis after 2 weeks of treatment for nonspecific clinical signs (see Postmortem findings).
Feed consumption
There was a significant treatment-by-time interaction in average food consumption. Table 1 ). The increase in food consumption compared to controls correlated with body weight increases in all of the treated groups (see Table 2 ). It was unclear whether the effect on food consumption was due to cyclosporine.
Body weight
Body weights and body weight gains were slightly higher in treated animals than in controls throughout the study, although this was not statistically significant (Table 2) . It was unclear whether the affect on body weight was a direct effect of the cyclosporine or an indirect effect of increased food consumption.
Clinical pathology
There were no biologically relevant treatment-related effects on hematology, clinical chemistry, or urinalysis parameters at any dose in either sex. Prolonged APTT was seen at dose levels >19, but this was considered unlikely to be biologically relevant (Table 3) .
Plasma analyses
Pharmacokinetic parameters were calculated for cyclosporine profiles obtained on Day 182 at [h]: 0, 1, 2, 4, 8 and 24 (Table 4) . Increasing doses led to relatively lower C max, and AUC parameter estimates then predicted assuming dose proportionality (Fig. 1) . The estimated accumulation factors (R) after long-term dosing at 8 mg/kg/day, calculated as ratios of trough levels between Day 7 (i.e. at this time, steady-state is expected to be reached based on cyclosporine terminal half-life in cats (Mehl et al., 2003) ) and subsequent study days with available trough samples were in general not significantly different from 1, indicating no further significant accumulation at 19 ( Fig. 2) with long-term exposure. An exception was the single R factor value for the ratio of the trough level between Day 7 and Day 154, which was R = 1.72.
Postmortem findings
Postmortem findings were limited to the 40 mg/kg/day group (59). There was one unscheduled death, a female dosed at 40 mg/kg/day, which was euthanized in extremis after 2 weeks of treatment for nonspecific clinical signs including recumbency, inappetence, dehydration, and decreased body weight (loss of approximately 18%). Pathology findings showed a healing rib fracture (estimated to be about 2 weeks old) and bone marrow hypocellularity characterized by a moderate reduction in the number of bone marrow cells of multiple lineages. Hematology parameters collected prior to euthanasia were not consistent with the observed bone marrow hypocellularity. The cat's trough cyclosporine concentration was 4858.8 ng/mL, approximately fivefold higher than any other cat in the 59 group. Malignant lymphoma involving the kidneys and a mesenteric lymph node was present in a male treated with 40 mg/kg/day. In addition, a female cat in this same group presented with abdominal fibroadenomatous nodules during the study.
DISCUSSION
Although cyclosporine has been used in cats for some time, ATOPICA for Cats (cyclosporine oral solution, USP) MODIFIED has only recently been approved by the US FDA for the control of HD in cats of at least 6 months of age and 1.4 kg in body weight. As allergic dermatitis is a chronic condition, treatment at a dose of 7 mg/kg should be given for at least 4-6 weeks after which it can be tapered to maintain the desired therapeutic effect. Such long-term therapy raises concerns over toxicity, especially as it has been suggested that the blood concentration of CsA may increase over time due to saturation of the tissuebinding sites and adverse effects may be linked to high trough blood concentrations (>700 ng/mL) in cats also treated concomitantly with ketoconazole (Vaden, 1997; McAnulty & Lensmeyer, 1999) . However, results from a field study with 100 client owned cats with HD showed that treatment with 7.0 mg/kg cyclosporine for up to 6 weeks was efficacious and well tolerated (King et al., 2012) . The results of this present study confirm that CsA is safe and well tolerated by cats, even at multiples of the recommended dose of 7 mg/kg, given daily over a 6-month period. Few adverse reactions to cyclosporine have been reported in cats treated for allergic dermatoses. Gastrointestinal signs (diarrhea, vomiting and anorexia) are the most frequently observed reactions (Robson, 2003a; Noli & Scarampella, 2006; Vercelli et al., 2006; Wisselink & Willemse, 2009; Heinrich et al., 2011; King et al., 2012) . In a study conducted by Vercelli et al. (2006) , mild gastrointestinal signs (intermittent soft feces or occasional vomiting) were observed in 4/23 cats during the first week of treatment with 5-14 mg/kg CsA dosed twice daily while Noli and Scarampella (2006) observed mild diarrhea in 1/10 cats following daily dosing with 3.6-8.3 mg/kg for 1 month. Also, following 4 weeks of treatment with 5 mg/kg CsA once daily, 11 of 18 treated cats experienced some form of reversible mild adverse reaction, including intermittent vomiting (three cats), diarrhea or loose stools (five cats), hyperactivity, increased appetite, and polydipsia (Wisselink and Willemse, 2009) .
In the present study, following up to five times (59), the approved dose administered daily over a 6-month period, there was an increase in the frequency and number of male cats with 'soft feces', but in contrast to some reported observations in the field, there was no vomiting or anorexia. Indeed in our study, as in the study conducted by Wisselink and Willemse (2009), food intake was generally increased in treated cats when compared to control cats, which likely contributed to the observed increase in body weight. Wisselink and Willemse (2009) also reported an increase in white blood cell counts, but suggested this may be due to the underlying inflammatory skin condition rather than due to CsA as it was also observed in the control prednisolone treated cats. Hematological parameters remained within normal ranges for treated cats within this current study. Activated partial thromboplastin time (APTT) was prolonged in cats administered at least twice the recommended dose of CsA, with the greatest increase observed in the cats receiving the highest dose following a minimum of 4 weeks of treatment. These changes may be test article-related; however, they were mild and not considered biologically relevant. The APTT is a performance indicator measuring the efficacy of
